← Back to Screener
bioAffinity Technologies, Inc. Warrant (BIAFW)
Price$0.36
Favorite Metrics
Price vs S&P 500 (4W)5.14%
All Metrics
Price vs S&P 500 (YTD)2.31%
10-Day Avg Trading Volume0.00M
3-Month Avg Trading Volume0.00M
52-Week High$0.81
13-Week Price Return410.64%
3-Month Return Std Dev681.14%
Year-to-Date Return2.86%
5-Day Price Return-20.00%
Month-to-Date Return-20.44%
Price vs S&P 500 (13W)411.13%
Beta5.29x
52-Week Low$0.05
Industry Peers — R&D — Physical Sciences(10)
| Symbol | P/E Ratio (Annual) | ROE (TTM) | Revenue Growth (5Y) | Indicated Dividend Yield (Annual) | Price |
|---|---|---|---|---|---|
BIAFWbioAffinity Technologies, Inc. Warrant | — | — | — | — | $0.36 |
IQVIQVIA Holdings Inc. | 22.22x | 22.28% | 7.50% | — | $171.95 |
INCYIncyte Genomics Inc | 14.67x | 29.15% | 14.03% | — | $95.32 |
MEDPMedpace Holdings, Inc. Common Stock | 32.83x | 118.82% | 22.27% | — | $515.65 |
CRLCharles River Laboratories International, Inc. | — | -4.40% | 6.55% | — | $176.94 |
ABSIAbsci Corporation Common Stock | — | -59.68% | -10.14% | — | $3.23 |
NRCNational Research Corporation Common Stock (Delaware) | 34.98x | 58.51% | 0.61% | 3.59% | $17.62 |
OABIOmniAb, Inc. Common Stock | — | -23.99% | -4.31% | — | $1.56 |
MXCTMaxCyte, Inc. Common Stock | — | -24.06% | 4.76% | — | $0.82 |
NOTVInotiv, Inc. Common Stock | — | -50.77% | 53.35% | — | $0.30 |
ISPCiSpecimen Inc. Common Stock | — | -496.37% | -25.09% | — | $0.12 |
About
bioAffinity Technologies develops noninvasive diagnostic tests for early-stage cancer, particularly lung cancer, and targeted cancer therapeutics. Its proprietary CyPath Lung test uses technology that preferentially targets cancer cells to enable early-stage lung cancer detection without invasive procedures. The company addresses a significant clinical need for improved early cancer diagnosis and treatment options.